WHO backs two new Ebola vaccine candidates for trial in DR Congo
Health researchers in the Democratic Republic of the Congo are preparing to test two additional vaccine candidates against Bundibugyo virus, the cause of the country’s current Ebola outbreak. In a statement issued on 4 N.
Photo credit and license
Photo: Louie Rosencrans / CDC Global Health — CC BY 2.0; https://commons.wikimedia.org/wiki/File:Vaccination_in_Democratic_Republic_of_Congo_(34733084465).jpg. Original unmodified; contextual photograph. · Image source · License: CC BY 2.0Health researchers in the Democratic Republic of the Congo are preparing to test two additional vaccine candidates against Bundibugyo virus, the cause of the country’s current Ebola outbreak. In a statement issued on 4 November 2026, the World Health Organization said independent experts had recommended adding the candidates to the ongoing Tumaini clinical trial. Their entry remains subject to national regulatory approval. The announcement concerns research, not the rollout of vaccines already proven to prevent infection.
The candidates use different approaches. ChAdOx1 was developed by the University of Oxford together with the Serum Institute of India; the other, mRNA-1469, comes from Moderna. Both are intended to address Bundibugyo virus specifically. WHO says its technical advisory group assessed available preclinical and early clinical evidence before recommending that they be evaluated during an active outbreak. The effectiveness of either candidate against the disease in these conditions has not yet been demonstrated.
Tumaini is structured as a multi-candidate study using ring vaccination: researchers identify and invite contacts of people with confirmed disease. Four vaccination rings had already been established when WHO issued its update, with others being prepared. The Institut National de Recherche Biomédicale in the DRC leads the vaccine study with international research and public-health partners. This design may produce useful evidence in the locations where people are currently at risk, while also raising demanding ethical and operational questions for investigators.
Research into treatment is proceeding separately. The WHO-sponsored PARTNERS trial is assessing the antibody MBP134, the antiviral remdesivir and their combination in people with confirmed Bundibugyo virus disease; another antibody treatment, maftivimab, is expected to join. These medicines are being studied as possible treatments, not established cures. WHO said initial treatment findings are expected in the coming months, while vaccine results could emerge in early 2027. Both schedules are projections and may change.
The announcement reflects the difficult distinction between a promising medical candidate and a validated public-health tool. A trial can establish whether a vaccine is safe and effective; a recommendation to test it cannot. The outbreak response still depends on surveillance, contact tracing, infection prevention, clinical care and public cooperation. For communities affected by the epidemic, research progress matters most if it eventually leads to reliable protection and accessible care.